SLXN

NASDAQ 已收盘

Silexion Therapeutics

1.31 USD
▼-0.19-12.67%
盘后 1.25 -4.58%
2026-11-20
市值
$303.50K
市盈率
—
EPS
-929.85
股息率
—
52 周区间
1.26 – 777.12
成交量
16.45K
Beta
-0.29
目标价
60.00
52W 低 1.2652W 高 777.12
价格走势

公司简介

Silexion Therapeutics Corp operates as a clinical-stage oncology-focused biotechnology company. It engages in the development of treatments for unsatisfactorily treated solid tumor cancers. The company is advancing its lead product candidate, SIL204, a small interfering RNA (siRNA) through Phase 2/3 clinical evaluation. It focuses on therapeutic advancements in the field of oncology, as well as developing its lead product candidate for pancreatic cancer. The company was founded in 2008 and is headquartered in Ramat Gan, Israel.